Table 1.
Summary of randomized, controlled studies of vasoconstrictor therapy in patients with type 1 hepatorenal syndrome
| Author | Year | Treatment | Patients | Hepatorenal Syndrome Reversal, % | Mortality without Transplantation, % | Transplantation, % |
|---|---|---|---|---|---|---|
| Alessandria et al. (27) | 2007 | Terlipressin | 12 | 83 | 90 | 66 |
| Norepinephrine | 10 | 70 | 100 | 70 | ||
| Sharma et al. (28) | 2008 | Terlipressin | 20 | 50 | 45 | — |
| Norepinephrine | 20 | 50 | 45 | — | ||
| Sanyal et al. (21) | 2008 | Terlipressin | 56 | 34 | 87 | — |
| Placebo | 56 | 13 | 91 | — | ||
| Martin-Llahí et al. (20) | 2008 | Terlipressin | 23 | 44 | 73 | 0 |
| Albumin | 23 | 9 | 81 | 4 | ||
| Singh et al. (29) | 2012 | Terlipressin | 23 | 39 | 61 | 0 |
| Norepinephrine | 23 | 43 | 52 | 0 | ||
| Cavallin et al. (19) | 2015 | Terlipressin | 27 | 70 | 41 | 0 |
| Midodrine | 22 | 29 | 57 | 4 | ||
| Boyer et al. (23) | 2016 | Terlipressin | 97 | 24 | 42 | — |
| Albumin | 99 | 15 | 46 | — | ||
| Arora et al. (22) | 2018 | Terlipressin | 60 | 40 | 52 | — |
| Noradrenaline | 60 | 17 | 80 | — |
All treatment arms included albumin. —, not available.